A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy
NCT06351904
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
72
Enrollment
OTHER
Sponsor class
Conditions
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Interventions
DRUG:
RAG-01
Sponsor
Ractigen Therapeutics.